|04/27/17||Pacira Pharmaceuticals Announces Timing for First Quarter 2017 Financial Results Webcast and Conference Call|
|PARSIPPANY, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 4, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialing 1-... |
|04/03/17||Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference|
|PARSIPPANY, N.J., April 03, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 16th Annual Needham Healthcare Conference at 3:00 PM ET on Tuesday, April 4, 2017, in New York.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira web... |
|03/16/17||Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide|
|Collaboration will develop and standardize evidence-based, low-opioid strategies across Trinity Health's 22 states to benefit people and communities
PARSIPPANY, N. J. and LIVONIA, Mich., March 16, 2017 (GLOBE NEWSWIRE) -- Trinity Health, one of the largest hospital systems in the nation, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced they will collaborate to develop an alternative approach to opioids for pain management.
|03/14/17||Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption and Postsurgical Pain in Patients Undergoing Total Knee Arthroplasty|
|Multicenter randomized study serves as unequivocal evidence of EXPAREL as an opioid minimizing agent in a complex and painful surgical procedure
Protocol’s best practice infiltration technique for the use of EXPAREL will be focus of educational programs at American Academy of Orthopaedic Surgeons Annual Meeting
PARSIPPANY, N.J. , March 14, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspensi... |